Sientra (NASDAQ: SIEN) and Syneron Medical (NASDAQ:ELOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Sientra and Syneron Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sientra -169.77% -68.82% -43.13%
Syneron Medical -1.09% -1.74% -1.30%

Analyst Recommendations

This is a summary of current recommendations and price targets for Sientra and Syneron Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sientra 0 1 4 0 2.80
Syneron Medical 0 1 0 0 2.00

Sientra presently has a consensus price target of $13.75, indicating a potential upside of 1.85%. Syneron Medical has a consensus price target of $11.00, indicating a potential upside of 0.00%. Given Sientra’s stronger consensus rating and higher probable upside, research analysts plainly believe Sientra is more favorable than Syneron Medical.

Insider and Institutional Ownership

77.6% of Sientra shares are held by institutional investors. Comparatively, 69.2% of Syneron Medical shares are held by institutional investors. 28.1% of Sientra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sientra and Syneron Medical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Sientra $20.73 million 12.63 -$40.16 million ($2.85) -4.74
Syneron Medical N/A N/A N/A N/A N/A

Syneron Medical has higher revenue, but lower earnings than Sientra.

Risk and Volatility

Sientra has a beta of -1.45, meaning that its share price is 245% less volatile than the S&P 500. Comparatively, Syneron Medical has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Summary

Sientra beats Syneron Medical on 6 of the 10 factors compared between the two stocks.

Sientra Company Profile

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Syneron Medical Company Profile

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company’s products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.